103rd Day Of Lockdown

Maharashtra2000641080828671 Tamil Nadu107001605921450 Delhi97200682563004 Gujarat35398254141926 Uttar Pradesh2655418154773 Telangana2231211537288 Karnataka215499246335 West Bengal2123114166736 Rajasthan1975615663453 Andhra Pradesh186978422232 Haryana1669012493260 Madhya Pradesh1460411234598 Bihar11860876590 Assam11002674414 Odisha9070622446 Jammu and Kashmir82465143127 Punjab61094306162 Kerala5205304826 Chhatisgarh3161252614 Uttarakhand3093250242 Jharkhand2739203514 Goa16848256 Tripura155812021 Manipur13256670 Himachal Pradesh104871510 Puducherry94644814 Nagaland5782280 Chandigarh4663956 Arunachal Pradesh252751 Mizoram1601230 Sikkim101520 Meghalaya50421
Lifestyle Health and Wellbeing 25 Nov 2019 AI hits another mile ...

AI hits another milestone; to determine if lung patients benefit from immunotherapy

ANI
Published Nov 25, 2019, 12:05 pm IST
Updated Nov 25, 2019, 12:05 pm IST
Artificial Intelligence to determine whether immunotherapy is working.
This suggests that those CT scans actually appear to capture the immune response elicited by the tumours against the invasion of cancer. (Photo: ANI)
 This suggests that those CT scans actually appear to capture the immune response elicited by the tumours against the invasion of cancer. (Photo: ANI)

Washington: Researchers working on Artificial Intelligence has hit another milestone as they have found a way to predict if a lung-cancer patient can be benefitted from expensive immunotherapy. And, once again, they're doing it by teaching a computer to find previously unseen changes in patterns in CT scans taken when the lung cancer is first diagnosed compared to scans taken after the first 2-3 cycles of immunotherapy treatment.

"This is no flash in the pan -- this research really seems to be reflecting something about the very biology of the disease, about which is the more aggressive phenotype, and that's information oncologists do not currently have," said Anant Madabhushi, who works at Centre for Computational Imaging and Personalised Diagnostics (CCIPD).

 

Madabhushi said the recent work by his lab would help oncologists know which patients would actually benefit from the therapy, and who would not. "Even though immunotherapy has changed the entire ecosystem of cancer, it also remains extremely expensive -- about USD 200,000 per patient, per year," Madabhushi said.

"That's part of the financial toxicity that comes along with cancer and results in about 42 per cent of all newly diagnosed cancer patients losing their life savings within a year of diagnosis," added Madabhushi. Having a tool based on the research being done now by his lab would go a long way toward "doing a better job of matching up which patients will respond to immunotherapy instead of throwing USD 800,000 down the drain," he added, referencing the four patients out of five who will not benefit, multiplied by annual estimated cost.

The new research, led by co-authors Mohammadhadi Khorrami and Prateek Prasanna, along with Madabhushi and 10 other collaborators from six different institutions (see the list, below) was published in the journal -- Cancer Immunology Research.

Khorrami, a graduate student working at the CCIPD, said one of the more significant advances in the research was the ability of the computer program to note the changes in texture, volume and shape of a given lesion, not just its size.

"This is important because when a doctor decides based on CT images alone whether a patient has responded to therapy, it is often based on the size of the lesion," Khorrami said. "We have found that textural change is a better predictor of whether the therapy is working.

"Sometimes, for example, the nodule may appear larger after therapy because of another reason, say a broken vessel inside the tumour -- but the therapy is actually working. Now, we have a way of knowing that," added Khorrami.

Prasanna, a postdoctoral research associate in Madabhushi's lab, said the study also showed that the results were consistent across scans of patients treated at two different sites and with three different types of immunotherapy agents. Prasanna added the initial study used CT scans from 50 patients to train the computer and create a mathematical algorithm to identify the changes in the lesion.

Additionally, Madabhushi said, researchers were able to show that the patterns on the CT scans which were most associated with a positive response to treatment and with overall patient survival were also later found to be closely associated with the arrangement of immune cells on the original diagnostic biopsies of those patients.

This suggests that those CT scans actually appear to capture the immune response elicited by the tumours against the invasion of cancer -- and that the ones with the strongest immune response were showing the most significant textural change and most importantly, would best respond to the immunotherapy, he said.

...




ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT